PRESSEMITTEILUNGEN

(pressebox) Martinsried/München und US-Standort in Princeton, N.J., 02.06.2009, . – Analysen der Ergebnisse der SPARC-Studie zeigen, dass Schmerzempfinden bei Studieneintritt, Zunahme des Schmerzempfindens sowie progressionsfreies Überleben drei Monate nach Studieneintritt, prädiktive Parameter bezüglich des Gesamtüberlebens bei metastasiertem, kastrationsrefraktärem, Docetaxel-vorbehandeltem Prostatakrebs sind – Weitere Daten aus Studien, die Satraplatin in Kombination mit verschiedenen Krebstherapien untersuchen, wurden [...]

Continue reading

Asco, Baseline, Chemotherapie, Docetaxel, Gpc Biotech Ag, Krankheit, Orlando Florida, Phase 3, Placebo, Prednison, Prednisone, Princeton, Prostatakrebs, Prostate Cancer, Prostate Cancer Results, Refractory Prostate Cancer, Satraplatin, Sparc, Survival, Therapie

Biomarker mPITX2 für die Prognoseeinschätzung bei Prostatakrebs erfolgreich validiert Erstes klinisches Labor in Deutschland wird mPTIX2-Test anbieten ——————————————————————————– Corporate News übermittelt durch euro adhoc. Für den Inhalt ist der Emittent/Meldungsgeber verantwortlich. ——————————————————————————– Produkte/Forschung/Molekulardiagnostik Pressemitteilung, Berlin, und Seattle, USA, 29. Mai 2009 (euro adhoc) – Die Epigenomics AG (Frankfurt Prime Standard: ECX), ein Molekulardiagnostik- Unternehmen mit [...]

Continue reading

Adhoc, Asco, Corporate News, Dna, Ecx, Epigenomics, Heiden, Krebs, Methylation, Oncology, Organs, Orlando Florida Usa, Prime Standard, Prostate Cancer, Prostate Cancer Patients, Prostatectomy, Recurrence, Risiko, Seattle Usa

Biomarker mPITX2 for prostate cancer prognostic application successfully validated First clinical laboratory in Germany to start offering mPITX2 testing service ——————————————————————————– Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. ——————————————————————————– new product/research/Molecular diagnostics Press release, Berlin, Germany and Seattle, WA, USA, May 29, 2009 (euro adhoc) [...]

Continue reading

Berlin Germany, Cancer Detection, Disease Recurrence, Dna Methylation, Eans, Epigenomics Ag, Molecular Diagnostics, New Product Research, Orlando Florida Usa, Poster Presentation, Prime Standard, Prostate Cancer, Prostate Cancer Patients, Prostate Cancer Prognosis, Prostate Cancer Risk, Prostatectomy, Rational Design, Risk Groups, Seattle Wa Usa, Validation Study

Patents cover biomarker mPITX2 for prostate and breast cancer indications ——————————————————————————– Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. ——————————————————————————– new product/molecular diagnostics Berlin, Germany, and Seattle, WA, USA, May 13, 2009 (euro adhoc) – Epigenomics AG (Frankfurt Prime Standard: ECX), a molecular diagnostics company focusing [...]

Continue reading

American Urological Association, Breast Cancer, Breast Cancer Patients, Cancer Detection, Cancer Indications, Disease Recurrence, Dna Methylation, Duke University, Epigenomics Ag, European Patent Office, Patent And Trademark Office, Patent Application, Patent Applications, Prostate Cancer, Prostate Cancer Prognosis, Seattle Wa Usa, United States Patent, United States Patent And Trademark Office, Urology Community, Validation Study

——————————————————————————– Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. ——————————————————————————– finances/molecular diagnostics Berlin, Germany and Seattle, WA, U.S.A., May 11, 2009 (euro adhoc) – Key Figures . Revenue: EUR 1.24 million in Q1 2009, up by 36% (Q1 2008: EUR 0.92 million) . EBIT: EUR -2.31 [...]

Continue reading

31 Million, Adhoc, Berlin Germany, Biomarker, Bioscience, Clinical Evaluation, Colorectal, Colorectal Cancer, Commercial Partnerships, Dna Methylation, Eans, Epigenomics Ag, Eur 2, Liquid Assets, Lung Cancer, Molecular Diagnostics, Prime Standard, Product Launch, Prostate Cancer, Quest Diagnostics

(pressebox) Berlin, 05.05.2009, In the first quarter 2009 the Berlin based Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700), a specialist for isotope technology in medicine, science and industry, in the first quarter 2009 set new records with sales of EUR 24 million and Group profits of EUR 2.2 million, thus far exceeding the [...]

Continue reading

Contrast Media, Earnings Per Share, Eckert, Economies Of Scale, Emission Tomography, Growth Trend, Industry Segment, Medicine Science, Medizintechnik, Minority Interests, New Hights, Nuclear Imaging, Positron Emission Tomography Pet, Profit Loss, Prostate Cancer, Radiation Equipment, Rate Improvement, Record Earnings, Segment Sales, Usd Exchange Rate

——————————————————————————– Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. ——————————————————————————– cooperations/molecular diagnostics Berlin, Germany and Seattle, WA, U.S.A., (euro adhoc) – April 28, 2009 – Epigenomics AG (Frankfurt, Prime Standard: ECX), a cancer molecular diagnostics company, today announced that it has entered into a non-exclusive licensing [...]

Continue reading

Adhoc, Berlin Germany, Cancer Death, Cancer Test, Cancer Tests, Cause Of Cancer, Dna Methylation, Eans, Elevated Psa, Epigenomics Ag, Health Outcomes, Histology, Histopathology, Molecular Diagnostic Tests, Molecular Diagnostics, Predictive Biosciences, Prime Standard, Prostate Biopsies, Prostate Cancer, Prostate Cancer Diagnosis

Arnheim, Niederlande (ots/PRNewswire) – Die European Association of Urology (EAU) hat die neuesten wissenschaftlichen Erkenntnisse aus randomisierten Screening-Studien zu Prostatakrebs geprüft (Schröder et al, NEJM 2009). Auf der Grundlage der Ergebnisse der European Randomised Study for Screening of Prostate Cancer (ERSPC) hat die EAU ein Positionspapier zum Thema Prostatakrebs-Screening in Europa und die durch die [...]

Continue reading

England Journal Of Medicine, Europa, Journal Of Medicine, Lunge, Medicine, Nejm, New England, New England Journal, New England Journal Of Medicine, Niederlande, Prostata, Prostatakrebs, Prostate Cancer, Psa Test, Randomised Study, Urology

Successfully delivering on new partnering deals – PRESEPT clinical trial on track – Product launches expected in 2009 – Financials in line with latest expectations – Two successful financing transactions ——————————————————————————– ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for the content of this announcement. ——————————————————————————– balance/molecular diagnostics Press Release, Berlin, Germany and Seattle, [...]

Continue reading

Adhoc, Berlin Germany, Biomarker, Blood Test, Centocor, Clinical Evaluation, Colorectal, Colorectal Cancer, Ebit, Epigenomics, Eur 1, Launch, Liquidity Position, Lung Cancer, Molecular Diagnostics, Operational Costs, Prostate Cancer, Quest Diagnostics, Seattle Wa Usa, Sysmex Corporation

Stockholm (ots/PRNewswire) – – Zu Händen: Gesundheits-Redakteure Laut Ergebnissen der ERSPC (European Randomized Study of Screening for Prostate Cancer)-Studie, die am 18. März um 17:00 Uhr MEZ online veröffentlicht wurde (New England Journal of Medicine (NEJM), Online-Erstveröffentlichung*), kann ein Screening auf Prostatakrebs die Zahl der Todesfälle um 20% senken. Die ERSPC-Studie ist die weltweit grösste [...]

Continue reading

Die Schweiz, England Journal Of Medicine, Journal Of Medicine, Lle, Medicine, Nejm, New England, New England Journal, New England Journal Of Medicine, Prostatakrebs, Prostate Cancer, Psa Screening, Randomized Study, Stockholm, Verlauf, Werts

——————————————————————————– ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for the content of this announcement. ——————————————————————————– cooperations/Molecular Diagnostics Berlin, Germany and Seattle, WA, U.S.A. (euro adhoc) – February 25, 2009 – Epigenomics AG (Frankfurt, Prime Standard: ECX), a cancer molecular diagnostics company, today announced that it has entered into a non-exclusive licensing agreement for [...]

Continue reading

Angelman Syndromes, Berlin Germany, Biopsies, Cancer Death, Cancer Test, Cause Of Cancer, Dgx, Diagnostic Testing, Dna Methylation, Elevated Psa, Epigenomics Ag, Faulty Dna, Histology, Histopathology, Molecular Diagnostics, Prime Standard, Prostate Cancer, Prostate Cancer Diagnosis, Quest Diagnostics, Today Announced That

——————————————————————————– ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for the content of this announcement. ——————————————————————————– companies/Diagnostics Berlin (euro adhoc) – 12. February 2009 – Epigenomics AG (Frankfurt, Prime Standard: ECX; ISIN: DE000A0BVT96) successfully placed all 2,671,088 new shares that were issued in an increase of the share capital against contribution in cash and [...]

Continue reading

Adhoc, Bb Medtech, Cancer Programs, Capital Llc, Colorectal, Diagnostic Test, Ecx, Epigenomics Ag, Frankfurt Germany, Frankfurt Stock Exchange, Gross Proceeds, Lung Cancer, Prime Standard, Prostate Cancer, Schaffhausen Switzerland, Share Capital, Subscription Rights, Supervisory Boards, Trout Capital, Weighted Average

——————————————————————————– Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. ——————————————————————————– 11.02.2009 Berlin, Germany – Epigenomics AG (Frankfurt, Prime Standard: ECX; ISIN: DE000A0BVT96) announces that the Executive Board and Supervisory Board have resolved today to increase the share capital of the company against contribution in cash and without [...]

Continue reading

Adhoc, Bb Medtech, Berlin Germany, Cancer Programs, Colorectal, Diagnostic Test, Ecx, Epigenomics, Gross Proceeds, Institutional Investors, Kno, Lung Cancer, Prime Standard, Private Placement, Prostate Cancer, Schaffhausen Switzerland, Share Capital, Subscription Rights, Supervisory Board, Weighted Average

Saint Prex, Switzerland (ots/PRNewswire) – – New Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist Demonstrates Rapid, Long-Term Suppression of Testosterone Ferring Pharmaceuticals received today notification that the Committee for Medicinal Products for Human Use (CHMP), part of the European Medicines Agency (EMEA), has adopted a positive opinion and is recommending to grant a marketing authorization for FIRMAGON(R) [...]

Continue reading

Cancer Saint, Chmp, European Medicines, Ferring Pharmaceuticals, Gonadotropin Releasing Hormone, Leuprorelin, Medicines Agency, Parallel Group Study, Prnewswire, Prostate Cancer, Prostate Cancer Cells, Prostate Cancer Patients, Prostate Specific Antigen, Psa Levels, Receptor Antagonist, Saint Prex, Serum Testosterone, Study Patients, Testosterone Levels, Treatment Of Prostate Cancer